MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Open-label, dose-confirmation and cohort expansion, multicentre, Phase Ib/II study to assess
the anti-tumour activity and safety of MEN1611 in combination with cetuximab for the
treatment of patients with PIK3CA mutated metastatic colorectal cancer.